Despite Steep Costs, Payments for New Cancer Drugs Make Economic Sense
Download
Download
Download
Full text for this resource is not available from the Research Repository.
Export
Lichtenberg, Frank R (2011) Despite Steep Costs, Payments for New Cancer Drugs Make Economic Sense. Nature Medicine, 17 (3). p. 244. ISSN 1078-8956
Abstract
Cancer drugs have become more expensive over the past few years, leading many people to question whether the treatments are really worth their high costs. But despite the sticker shock, cancer medicines have provided good value for money.
| Item type | Article |
| URI | https://vuir.vu.edu.au/id/eprint/9443 |
| Official URL | http://www.nature.com/nm/journal/v17/n3/pdf/nm0311... |
| Subjects | Historical > FOR Classification > 1112 Oncology and Carcinogenesis Historical > FOR Classification > 1402 Applied Economics Historical > SEO Classification > 970114 Expanding Knowledge in Economics Historical > Faculty/School/Research Centre/Department > Centre for Strategic Economic Studies (CSES) |
| Keywords | ResPubID24425, Avastin, Rituxan, Gleevec, Herceptin, cancer therapy, survival rate |
| Citations in Scopus | 8 - View on Scopus |
| Download/View statistics | View download statistics for this item |
CORE (COnnecting REpositories)